Access Pharmaceuticals Reveals Results from MuGard Phase 4 Trial by

ACCESS PHARMACEUTICALS, INC. a biopharmaceutical company establishing therapies in fields of oncology and oncology supportive care, introduced that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, introduced achievements from its continuing MuGard Phase 4 assessments in oral mucositis (OM) with the Multinational Association of Supportive Care in Cancer (MASCC) Conference in New York City.

The preview summarized facts from 70 cancer affected individuals going through chemo radiation session for head and neck cancer. Affected individuals using MuGard skilled a statistically significant lowering of mouth and throat swelling, a statistically significant postpone to actually onset of oral mucositis as checked in days or cumulative radiation hazard, and statistically large reductions in losing weight during therapy as well as in using opioid discomfort prescriptions.

"Offered the extensive oral mucositis typically found in this head and neck cancer inhabitants, the rewards of MuGard shown in the achievements out of this trial are vital both clinically and using an affected person quality-of-life viewpoint. It's crucial that we keep affected individuals as cozy and fed as possible within this tough therapy regimen, to actually optimize clinical consequences," stated Dr. Ron R. Allison, an investigator within the MuGard trial, Carolina Radiation Medicine, Greenville, NC.